CF vs SION: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CF and SION share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CF and SION exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CF Industries Holdings makes nitrogen products, primarily anhydrous ammonia, granular urea, and urea ammonium nitrate (UAN) solution, along with ammonium nitrate and diesel exhaust fluid. It is the world's largest producer of ammonia and North America's largest pure-play nitrogen manufacturer, running a fleet of gas-fed plants across the US, Canada, and the UK. Natural gas is its main feedstock, so its cost position is structurally advantaged when North American gas is cheap relative to European and Asian producers.

Full CF guide

Sionna Therapeutics (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF). Its candidates are first-in-class stabilizers of the nucleotide-binding domain 1 (NBD1) of the CFTR protein, the region disrupted by the F508del mutation that affects roughly 90% of CF patients. The original thesis was that stabilizing NBD1 could restore CFTR function toward wild-type levels and, added on top of the current standard of care (Vertex's Trikafta), deliver clinically meaningful improvement. The company went public in February 2025 at $18.00 per share, raising about $219 million in an upsized IPO.

Full SION guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CF drivers: Tight global nitrogen supply and pricing; Low-cost North American natural gas feedstock.
• SION drivers: The SION-451 + SION-2222 combination; NBD1 mechanism after the setback.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CF's earnings are highly cyclical and tied to volatile nitrogen prices, which can fall sharply when global supply loosens or demand softens. For SION, as a pre-revenue clinical-stage biotech that has already had one major trial failure, Sionna faces the standard binary risk that the next trial disappoints as well.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CF if you believe its drivers more; SION if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CF and SION guides.

CF. At about 8.9 times trailing earnings and 10.7 times forward, CF's multiple rises as you look ahead because consensus expects EPS to fall roughly 25% in 2027 from a 2026 peak near $15.20, the usual shape for a cyclical commodity producer near the top of its cycle. Second quarter EPS of $4.73 missed a $5.57 consensus despite record-scale revenue, and the third quarter report on November 4, 2026 carries a consensus near $2.91 on about $1.77 billion of revenue. The mean analyst target of about $128 sits modestly above the October 16 price, with views spread widely, from a $110 target at Redburn to $162 at Bernstein.

SION. SION has no product revenue and runs steady operating losses, which is normal for a clinical-stage biotech funding trials, so traditional earnings multiples do not apply. After the SION-719 failure the stock trades at roughly 0.65x book value, with a market cap of about $172 million against roughly $211-268 million of cash depending on the measure, which means the market is pricing the remaining pipeline at little or below zero. The next earnings report is expected around November 5, 2026 (an estimated date), with consensus calling for a loss of about $0.68 per share.

Headline figures (approximate, October 2026): CF shows revenue (ttm) ~$7.74B; Q2 2026 ~$2.22B, up ~18% year over year, net income (ttm) ~$2.1B (Q2 2026 ~$727M), margins (ttm) Gross ~42.5%, net ~27.1%, eps (ttm / 2026 consensus / 2027 consensus) ~$13.48 / ~$15.20 / ~$11.21; SION shows revenue (ttm) ~$0 (no approved product), net loss (ttm) ~$97M (Q2 2026 ~$30M; FY2025 ~$75M), eps (q2 2026) ~-$0.66 vs ~-$0.65 expected, cash & marketable securities ~$268M at June 30, 2026 (runway into 2H 2029).

CF and SION are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CF and SION exposure against your real portfolio. It is not an investment adviser.